Pragmatic or hybrid RCT designs comparing GLP-1RAs or SGLT2 inhibitors against standard care, with long-term follow-up for dementia and stroke incidence, would help determine true disease-modifying potential. This evidence concerns the gene SLC5A2 and stroke disorder.